9th Mar 2006 15:46
Skyepharma PLC09 March 2006 For Immediate Release 9 March 2006 SkyePharma PLC Extraordinary General Meeting LONDON, UK, 9 March 2006 - SkyePharma PLC (LSE: SKP; Nasdaq: SKYE) announces theresults of the voting at the Extraordinary General Meeting held today. Theresolution considered by the meeting was the appointment of Mr Robert Thian as adirector. The resolution was rejected by a significant proportion of both votesand number of shareholders. The resolution to appoint Mr Thian as a director was defeated by a majority of28.5 million shares For the resolution: 225,843,014 votes (880 shareholders) Against the resolution: 254,377,799 votes (2984 shareholders) In terms of votes cast, 53% of votes were against the resolution and 47% werefor the resolution. In terms of the number of shareholders voting, 23% voted forthe resolution and 77% against. Dr Jerry Karabelas, SkyePharma's Non-Executive Chairman, said: "The EGM is nowbehind us. We can now get on with running the business for the benefit of allshareholders." For further information please contact: SkyePharma PLC +44 207 491 1777Frank Condella, Chief Executive OfficerPeter Laing, Director of Corporate Communications +44 207 491 5124 Sandra Haughton, US Investor Relations +1 212 753 5780 Buchanan Communications +44 207 466 5000Tim Anderson / Mark Court/Rebecca Skye Dietrich Notes for editors: About SkyePharma SkyePharma PLC develops pharmaceutical products benefiting from world-leadingdrug delivery technologies that provide easier-to-use and more effective drugformulations. There are now eleven approved products incorporating SkyePharma'stechnologies in the areas of oral, injectable, inhaled and topical delivery,supported by advanced solubilisation capabilities. For more information, visitwww.skyepharma.com. Certain statements in this news release are forward-looking statements and aremade in reliance on the safe harbour provisions of the U.S. Private SecuritiesLitigation Act of 1995. Although SkyePharma believes that the expectationsreflected in these forward-looking statements are reasonable, it can give noassurance that these expectations will materialize. Because the expectations aresubject to risks and uncertainties, actual results may vary significantly fromthose expressed or implied by the forward-looking statements based upon a numberof factors, which are described in SkyePharma's 20-F and other documents on filewith the SEC. Factors that could cause differences between actual results andthose implied by the forward-looking statements contained in this news releaseinclude, without limitation, risks related to the development of new products,risks related to obtaining and maintaining regulatory approval for existing, newor expanded indications of existing and new products, risks related toSkyePharma's ability to manufacture products on a large scale or at all, risksrelated to SkyePharma's and its marketing partners' ability to market productson a large scale to maintain or expand market share in the face of changes incustomer requirements, competition and technological change, risks related toregulatory compliance, the risk of product liability claims, risks related tothe ownership and use of intellectual property, and risks related toSkyePharma's ability to manage growth. SkyePharma undertakes no obligation torevise or update any such forward-looking statement to reflect events orcircumstances after the date of this release. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
SKP.L